Phase IIa multicenter, randomized, double-blind, crossover, placebo-controlled trial to evaluate the safety and efficacy of BAY 2395840 in patients with diabetic neuropathic pain.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BAYER AG
- Phase: II
- Execution start: 24/01/2022
- End of execution: 22/11/2022
- IP: MARTIN LOPEZ DE LA TORRE CASARES
